1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

17 May 2024
Admin
News Article

Arexvy, the First RSV Vaccine for Older Adults, Granted Approval by HAS

Overview

Arexvy, the world's first respiratory syncytial virus (RSV) vaccine, has recently gained approval from the Health Sciences Authority (HSA) of Singapore for immunizing individuals aged 60 years and above against lower respiratory tract disease (LRTD) caused by RSV. This groundbreaking achievement underscores GSK's commitment to safeguarding the health of older adults in Singapore by providing protection against a range of infectious diseases.

Words from GSK Singapore

Raakhi Sippy, Vice President & General Manager of GSK Singapore, expressed satisfaction in introducing this vaccine to over one million older adults in Singapore, highlighting the extensive research and development efforts involved.
With a growing portfolio of adult vaccines, GSK aims to promote disease prevention and support healthier aging among Singapore's population.

RSV Infections: Impact

In 2019, RSV infections resulted in significant morbidity and mortality among individuals aged 60 and above globally, with millions of cases leading to hospitalizations and fatalities.
Studies conducted in Singapore have revealed a considerable prevalence of RSV infections among older adults, emphasizing the need for preventive measures.

RSV

RSV is a contagious virus primarily affecting the respiratory system and often presenting symptoms similar to other respiratory infections.
However, the impact of RSV can be particularly severe among individuals aged 60 and above, especially those with underlying medical conditions, leading to increased hospitalization rates and mortality.

AReSVi-006 Phase III trial

Clinical trial data from the AReSVi-006 Phase III trial demonstrated Arexvy's efficacy in preventing RSV-induced LRTD among older adults, with particularly promising results in those with underlying medical conditions.

RSV Infections in Older Adults

Dr. Stephanie Cinthu Stephen Ambrose, Country Medical Director at GSK Singapore, stressed the importance of protecting older adults from RSV infections, especially given Singapore's aging population trends.
As the population ages, prioritizing preventive measures against infectious diseases like RSV becomes increasingly crucial to maintaining the health and well-being of older adults.

Arexvy with AS01E Adjuvant

Arexvy, GSK's RSV vaccine for older adults, combines a recombinant subunit prefusion RSV F glycoprotein antigen (RSVPreF3) with GSK's proprietary AS01E adjuvant.
Approved in multiple countries, including Europe, Japan, the UK, Canada, and Australia, Arexvy has shown promise in preventing RSV-LRTD in individuals aged 60 and above.

AReSVi-006 Trial

The AReSVi-006 trial, conducted across 17 countries, aimed to demonstrate the efficacy of a single dose of GSK's RSV vaccine in individuals aged 60 and above, further validating its effectiveness in this vulnerable population.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!